Page 648 - Traité de Chimie Thérapeutique 4 Médicaments en relation avec des systèmes hormonaux

15- INHIBITEURS DE LA 5O.-RÉDUCTASE 609

Di SALLE E. et al. Hormonal effects of turosteride, a 5a-reductase inhibitor, in the rat.
J. Steroid. Biochem. Molec. Biol., 1993,46, 549-555.
DRUGS OFTHE FUTURE, 1991, 16, 996-1000. 1993,18, 436-439, 701-703.
FLESHNER N.E. et al. Treatment of advanced prostate cancer with the combination of
finasteride plus flutamide : early results. Eur. Urol., 1993, 24 (suppl.2), 106-112.
GELDOF A.A. et al. Considération of the use of 17p-W,M-diethylcarbamoyl-4-methyl-
4-aza-5a-androstan-3-one (4MA) a 5a-reductase inhibitor in prostate cancer the-
rapy. J. Cancer Res. Clin. Oncol., 1992,118, 50-55.
GELLER J. Effect of finasteride, a 5a-reductase inhibitor on prostate tissue androgens
and prostate-specific antigen. J. Clin. Endocrinol, and Metabolism, 1990, 71, 1552-
1555.
GORMLEY G.J. Rôle of 5a-reductase inhibitors in the treatment of advanced prostatic
carcinoma. Advanced Prostatic Carcinoma. Urologie Clinics of North America,
1991, 18, 93-97.
LABRIE C. Combination of an antiandrogen and a 5a-reductase inhibitor : a further
step towards total androgen blockade ? Endocrinology, 1991,129, 566-568.
LAMB J.C. et al. Prostatic involution in rats induced by a novel 5a-reductase inhibitor,
SK & F 105657 : rôle for testosterone in the androgénie response. Endocrinology,
1992, 130, 685-694.
LEVY M.A. et al. Inhibition of rat liver steroid 5a-reductase by 3-androstene-3-car-
boxylic acids : mechanism of enzyme-inhibitor interaction. Biochemistry, 1990, 29,
2815-2824.
METCALF B.W. et al. Inhibitors of steroid 5a-reductase in benign prostatic hyperpla-
sia, male pattern baldness and acné. T.I.P.S., 1989,10, 491-495.
PETERS D.H. et al. Finasteride, a review of its potential in the treatment of benign
prostatic hyperplasia. Drugs, 1993, 46 (1), 177-208.
PRESTI J.C. et al. Multicenter randomized, double blind, placebo controlled study to
investigate the effect of finasteride (MK-906) on stage D prostate cancer. The
Journal of Urology, 1992, 148, 1201-1204.
SCHWARTZ J. et al. Pharmacodynamies of a new 5a-reductase inhibitor (MK 0963) :
effets on sérum androgens. Clinical Pharmacology and Therapeutics, 1993, 53 (2),
231.
THIPGEN A.E. et al. Tissue distribution and ontogeny of steroid 5a-reductase isozyme
expression. J. Clin. Invest., 1993, 92, 903-910.
VERMEULEN A. et al. Hormonal effects of an orally active 4-azasteroid inhibitor of 5a-
reductase in humans. The Prostate, 1989,14, 45-53.